Azamethiphos (Alfron) is a veterinary-grade organothiophosphate active pharmaceutical ingredient supplied under the Alfron brand for formulation into tablets, injections, capsules, powders, granules, premixes, and solutions. The Alfron designation identifies the manufacturer’s controlled API grade, not a separate chemical entity. The substance is S-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl] O,O-dimethyl phosphorothioate, CAS 35575-96-3, with molecular weight 324.68 g/mol. As an organophosphate, its pharmacological action depends on inhibition of acetylcholinesterase at the active-site serine; this differs from pyrethroid sodium-channel modulation and macrocyclic lactone glutamate-gated chloride channel potentiation.

The material is produced as a white to off-white crystalline powder and is distinct from technical-grade azamethiphos used in environmental or aquaculture applications by tighter residual-solvent, elemental-impurity, and related-substance controls aligned with ICH Q3C, ICH Q3D, and veterinary GMP. Each batch is released against a certificate of analysis containing assay, related substances, residual solvents, water, elemental impurities, particle-size distribution, and microbial limits. Because no pharmacopoeial monograph for azamethiphos currently exists in Ph. Eur. or USP, the Alfron specification is an internal specification built from general monograph and ICH requirements; the manufacturer’s current CoA remains the binding document. Packaging is typically double polyethylene liners within fibre or HDPE drums, with desiccant bags if the storage area cannot maintain relative humidity below 60%. Re-test dating is assigned from long-term stability chambers operated under ICH Q1A(R2) Zone II conditions at 25 °C/60% RH; accelerated storage at 40 °C/75% RH is used for transport risk assessment.

What Limits Aqueous Stability in Azamethiphos Formulations?

Organophosphate esters such as azamethiphos are susceptible to pH-dependent hydrolysis, with degradation accelerating under alkaline conditions and at elevated temperature. Preformulation studies should therefore include pH-stat profiling from pH 2.0 to 8.0 using the stability-indicating HPLC method described in Ph. Eur. 2.2.29. The parent compound must be resolved from desmethyl azamethiphos and the oxazolo-pyridinone leaving group. The pH of maximum stability is typically below neutral, but the Alfron forced-degradation report must be consulted before setting a target pH. For tablets, capsules, powders, granules, and premixes, the API should be protected from free moisture, alkaline excipients such as dibasic calcium phosphate dihydrate, and prolonged wet granulation. If aqueous granulation is unavoidable, the wet mass should be dried to a final water content ≤0.5% w/w by Karl Fischer titration (Ph. Eur. 2.5.32/USP <921>) before lubrication.

Hydrolysis kinetics can be followed by measuring parent compound loss and increase of desmethyl azamethiphos. The relative response factor for desmethyl azamethiphos should be established during method validation; if the RRF is outside 0.80–1.20, the HPLC method should use an external standard or correction factor. Forced degradation conditions used for method validation include 0.1 M hydrochloric acid at 60 °C for 24 h, 0.1 M sodium hydroxide at 40 °C for 24 h, and 3% hydrogen peroxide at room temperature for 24 h; peak purity should be verified by diode array or mass spectrometry. The acid and base challenge results are used to set the pH range for aqueous granulation or solution formulations. For solid dosage forms, the water content limit is a surrogate for hydrolytic risk; a final blend water content ≤0.5% w/w is typical for capsules and tablets containing azamethiphos.

Thermal degradation of solid azamethiphos under dry conditions is generally slower than solution-phase degradation, but basic residues from synthesis can create local high-pH microenvironments. Sulfated ash and elemental impurity limits therefore have stability relevance in addition to safety. If the API is exposed to micronization, the process can introduce amorphous content and surface moisture; jet milling with nitrogen at inlet temperature 40–60 °C and product temperature below 40 °C is preferred over mechanical milling. After micronization, the powder should be re-tested for water content and particle size before use.

Tablet and capsule development depends primarily on particle-size distribution and flow. A standard grade with D90 ≤100 µm is suitable for wet granulation, while a micronized grade with D90 ≤15 µm may be required for direct compression at low drug loading to avoid content uniformity failure. Geometric dilution with lactose monohydrate or microcrystalline cellulose should be performed before final blending; bin blender speeds of 15–25 rpm for 10–15 min are typical. On a 12-station rotary tablet press, compression forces between 8 kN and 20 kN are commonly used for veterinary tablets, but actual force must be adjusted to tablet hardness and disintegration limits specified in Ph. Eur. 2.9.1 and 2.9.3. Low-dose capsule filling on a dosator/tamping pin machine requires consistent plug formation; fill-weight variability should be monitored against Ph. Eur. 2.9.5 or USP <905>. If the API is cohesive, addition of 0.5–1.0% fumed silica improves flow, but fumed silica can increase moisture adsorption and should be dry-blended under controlled RH 60%.

When direct compression is not feasible because of poor flow or segregation, dry granulation by roller compaction is preferred over wet granulation because it avoids aqueous hydrolysis. Roller compaction forces of 10–20 kN/cm and screen milling through 1.0 mm or 0.8 mm screens produce granules with acceptable tabletability; the resulting granules should be assessed for friability and particle-size distribution by sieve analysis per Ph. Eur. 2.9.38. Wet granulation with water should be avoided unless the binder solution is buffered to the stable pH and drying can reduce water to ≤0.5% rapidly. Fluid-bed drying with inlet air temperature 50–70 °C and product temperature 35–45 °C is suitable for azamethiphos granules; final granule moisture is confirmed by Karl Fischer before tableting. Capsule shells with low moisture content, such as HPMC, are preferred over gelatin if the API is moisture-sensitive. Compatibility with shell preservatives and plasticisers should be checked by stability-indicating HPLC.

Premix and Solution Handling: pH, Solvent Selection, and Incompatibility Boundaries

For premix and granule applications, the API is usually adsorbed onto carriers such as lactose monohydrate, dried maize starch, or silica. Dry mixing in a ribbon blender at 10–15 rpm for 10 min after sieving through 500 µm screens is sufficient for standard carriers; high-shear mixer homogenisation should be limited to 3–5 min to avoid local temperature rise above 40 °C. Alkaline carriers such as dibasic calcium phosphate dihydrate are incompatible and should not be used. Premix homogeneity is affected by carrier particle size and density. If the carrier mean particle size differs from the API by more than 10-fold, segregation during transport and farm mixing may occur. Ribbon blender homogeneity testing should sample at least 10 locations and measure azamethiphos content by HPLC with a target relative standard deviation ≤5.0%. Granulation of premix with mineral oil or propylene glycol as a binder can reduce dust and improve adherence to feed pellets, but the binder must not raise the water activity or introduce alkaline contaminants.

For oral solutions, nonaqueous vehicles such as propylene glycol, glycerol formal, or medium-chain triglycerides are preferred over water because aqueous formulations require pH buffering below 7.0 and may still display limited shelf life. If oxidative degradation is shown in forced-degradation studies, butylated hydroxytoluene at 0.05–0.10% may be added, but it is not a default requirement. Solution formulations should be nitrogen-blanketed during manufacture and stored in amber borosilicate or stainless steel vessels. If pH adjustment is required, dilute hydrochloric acid or citric acid is preferred over sodium hydroxide because alkaline additions create local hydrolysis. The final solution should be filtered through a 0.45 µm or 0.22 µm membrane and tested for pH, assay, related substances, and microbial limits. For oral drench solutions, viscosity and palatability are additional quality attributes; for injectable solutions, sterility and bacterial endotoxins must meet Ph. Eur. 2.6.1/2.6.14.

Parenteral use presents the narrowest formulation window. Published data for injectable azamethiphos configurations is limited; therefore, preformulation must include pH-solubility profiling at 25 °C and 37 °C in compendial buffer systems, cosolvent screening with propylene glycol, PEG 400, and water-miscible nonaqueous vehicles. Terminal steam sterilization at 121 °C for 15 min should be considered only after the manufacturer’s thermal stability data show ≤2.0% total degradation; otherwise aseptic filtration through 0.22 µm membrane is required. Because organophosphates inhibit human acetylcholinesterase, injectable veterinary products must be prepared with dedicated lines, closed transfer systems, and cholinesterase monitoring in exposed personnel.

If a Formulation Requires Another Organophosphate, the Specification Cannot Be Transferred

Azamethiphos contains the 6-chloro-oxazolo[4,5-b]pyridine leaving group, whereas phoxim carries an α-cyanobenzylideneamino group and tetrachlorvinphos has a trichlorostyryl group. These structural differences affect hydrolysis rates, UV absorbance, and chromatographic retention; the Alfron specification therefore cannot be transferred directly from another organophosphate monograph. Azamethiphos phosphorylates the serine hydroxyl at the esteratic site of acetylcholinesterase, producing a stable phosphate ester and enzyme inactivation. This mode of action is shared with other organophosphates but differs from carbamates such as propoxur, which carbamylate the same enzyme and are more readily hydrolysed. In contrast to macrocyclic lactones such as ivermectin, azamethiphos does not act at glutamate-gated chloride channels; spectrum, resistance patterns, and safety margin must be evaluated separately for each target species. Technical-grade azamethiphos supplied for aquaculture bath treatment may meet different impurity and packaging standards and should not be repurposed into veterinary dosage forms without full re-qualification under ICH Q3C, ICH Q3D, and veterinary GMP.

Because azamethiphos is an organophosphate acetylcholinesterase inhibitor, handling requires local poison-schedule compliance and occupational exposure controls. Atropine sulfate and pralidoxime chloride should be available before production starts, and air monitoring for azamethiphos dust should be performed according to the manufacturer’s SDS. No human or non-target species safety claim is made without species-specific maximum residue limit data and regulatory approval in the destination market.